Biocytogen-B Shares Surge Over 9% as First-Quarter Net Profit Soars Nearly Ninefold to RMB104 Million

Deep News04-28

Biocytogen-B (02315) saw its shares rise more than 9% during the trading session. By the time of writing, the gain had narrowed slightly to a modest increase of 1.61%, with the share price currently at HKD 59.80 and a turnover of HKD 74.96 million.

The company released its first-quarter report for 2026, revealing a revenue of RMB 433 million, representing a year-on-year increase of 73.68%. Net profit attributable to shareholders reached RMB 104 million, surging 885.41% compared to the same period last year. Biocytogen primarily engages in pharmacodynamic services and model animal revenue. The significant growth in revenue during this period is mainly attributed to increased demand for pharmacodynamic services.

It is noteworthy that Biocytogen issued an announcement stating its intention to invest approximately RMB 1.6 billion in the construction of the Biocytogen Model Animal and Antibody Drug R&D Base Project through its wholly-owned subsidiary, Biocytogen Jiangsu Gene Biotechnology Co., Ltd. The construction will primarily include an animal center of about 96,000 square meters, experimental facilities covering approximately 30,000 square meters, and related supporting infrastructure.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1159470505?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-28 10:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159470505","market":"hk","top_or_hot":-1,"title":"Biocytogen-B Shares Surge Over 9% as First-Quarter Net Profit Soars Nearly Ninefold to RMB104 Million","media":"Deep News","content":"<p>Biocytogen-B (02315) saw its shares rise more than 9% during the trading session. By the time of writing, the gain had narrowed slightly to a modest increase of 1.61%, with the share price currently at HKD 59.80 and a turnover of HKD 74.96 million.</p>\n<p>The company released its first-quarter report for 2026, revealing a revenue of RMB 433 million, representing a year-on-year increase of 73.68%. Net profit attributable to shareholders reached RMB 104 million, surging 885.41% compared to the same period last year. Biocytogen primarily engages in pharmacodynamic services and model animal revenue. The significant growth in revenue during this period is mainly attributed to increased demand for pharmacodynamic services.</p>\n<p>It is noteworthy that Biocytogen issued an announcement stating its intention to invest approximately RMB 1.6 billion in the construction of the Biocytogen Model Animal and Antibody Drug R&D Base Project through its wholly-owned subsidiary, Biocytogen Jiangsu Gene Biotechnology Co., Ltd. The construction will primarily include an animal center of about 96,000 square meters, experimental facilities covering approximately 30,000 square meters, and related supporting infrastructure.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biocytogen-B Shares Surge Over 9% as First-Quarter Net Profit Soars Nearly Ninefold to RMB104 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiocytogen-B Shares Surge Over 9% as First-Quarter Net Profit Soars Nearly Ninefold to RMB104 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-04-28 10:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biocytogen-B (02315) saw its shares rise more than 9% during the trading session. By the time of writing, the gain had narrowed slightly to a modest increase of 1.61%, with the share price currently at HKD 59.80 and a turnover of HKD 74.96 million.</p>\n<p>The company released its first-quarter report for 2026, revealing a revenue of RMB 433 million, representing a year-on-year increase of 73.68%. Net profit attributable to shareholders reached RMB 104 million, surging 885.41% compared to the same period last year. Biocytogen primarily engages in pharmacodynamic services and model animal revenue. The significant growth in revenue during this period is mainly attributed to increased demand for pharmacodynamic services.</p>\n<p>It is noteworthy that Biocytogen issued an announcement stating its intention to invest approximately RMB 1.6 billion in the construction of the Biocytogen Model Animal and Antibody Drug R&D Base Project through its wholly-owned subsidiary, Biocytogen Jiangsu Gene Biotechnology Co., Ltd. The construction will primarily include an animal center of about 96,000 square meters, experimental facilities covering approximately 30,000 square meters, and related supporting infrastructure.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1159470505","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159470505","pubTimestamp":1777341731,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Biocytogen-B (02315) saw its shares rise more than 9% during the trading session. By the time of writing, the gain had narrowed slightly to a modest increase of 1.61%, with the share price currently...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688796":"百奥赛图","BK1161":"生物科技","BK0216":"研究试验","02315":"百奥赛图-B"},"translate_title":"百奥赛图-B股飙升逾9%，第一季度净利润飙升近9倍至人民币1.04亿元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688796":1,"02315":1},"content_text":"Biocytogen-B (02315) saw its shares rise more than 9% during the trading session. By the time of writing, the gain had narrowed slightly to a modest increase of 1.61%, with the share price currently at HKD 59.80 and a turnover of HKD 74.96 million.\nThe company released its first-quarter report for 2026, revealing a revenue of RMB 433 million, representing a year-on-year increase of 73.68%. Net profit attributable to shareholders reached RMB 104 million, surging 885.41% compared to the same period last year. Biocytogen primarily engages in pharmacodynamic services and model animal revenue. The significant growth in revenue during this period is mainly attributed to increased demand for pharmacodynamic services.\nIt is noteworthy that Biocytogen issued an announcement stating its intention to invest approximately RMB 1.6 billion in the construction of the Biocytogen Model Animal and Antibody Drug R&D Base Project through its wholly-owned subsidiary, Biocytogen Jiangsu Gene Biotechnology Co., Ltd. The construction will primarily include an animal center of about 96,000 square meters, experimental facilities covering approximately 30,000 square meters, and related supporting infrastructure.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1159470505","isCrawlerRequest":true}